Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
17 hedge funds and large institutions have $386K invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 4 closing their positions.
19% less funds holding
Funds holding: 21 → 17 (-4)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
76% less capital invested
Capital invested by funds: $1.64M → $386K (-$1.25M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$8.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$44K |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$22.7K |
| 3 |
ICM
Ionic Capital Management
New York
|
-$16.5K |
| 4 |
EFI
EHP Funds Inc
Toronto,
Canada
|
-$9.06K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$6.9K |
CLDI.WS Hedge Fund Activity: Q4 2023 in Review
17 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q4 2023, worth a combined $386K — down 76% from $1.64M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CLDI.WS and 0 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 1 added.
The largest buyer was Cowen and Company, adding an estimated $8.18K. The largest seller was Periscope Capital, exiting entirely with an estimated $44K sold.
- 17 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q4 2023, down from 21 in Q3 2023.
- Funds reported $386K of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q4 2023, down 76% quarter-over-quarter.
- 0 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q4 2023 and 4 closed out, a net change of -4 holders.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q4 2023 was Cowen and Company, an estimated $8.18K added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q4 2023 was Periscope Capital, an estimated $44K sold.
Based on aggregated 13F filings for Q4 2023.